Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy

Core Viewpoint - Longeveron Inc. has received a patent for the use of its proprietary mesenchymal stem cells (MSCs) to treat female sexual dysfunction, which is a significant unmet medical need affecting up to 46% of women, particularly as they age [1][3][8] Patent Information - The U.S. Patent No. 12,496,316 grants Longeveron patent rights until 2038, with potential for further extensions [2] - The patent covers methods for administering MSCs to improve sexual quality of life in female patients [8] Market Opportunity - Female sexual dysfunction is a common issue with limited treatment options, highlighting a substantial market opportunity for Longeveron's stem cell therapy [3][8] - The company plans to pursue licensing or partnership agreements for the development and commercialization of this therapy [4][8] Product Overview - Laromestrocel (LOMECEL-B) is derived from mesenchymal stem cells isolated from the bone marrow of young, healthy adult donors, and is designed to support the body's repair mechanisms [5][6] - The product has potential applications across various rare and aging-related diseases, with multiple mechanisms of action including anti-inflammatory and regenerative effects [5][6] Company Background - Longeveron is focused on developing regenerative medicines to address unmet medical needs, with a pipeline that includes treatments for hypoplastic left heart syndrome, Alzheimer's disease, and pediatric dilated cardiomyopathy [6]